Caresia Ana Paula, Castell-Conesa Joan, Negre Montserra, Mestre Antoni, Cuberas Gemma, Mañes Anabel, Maldonado Xavier
Nuclear Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Clin Transl Oncol. 2006 Oct;8(10):750-4. doi: 10.1007/s12094-006-0122-9.
The aim of this study was to establish the value of thalium-(201) single-photon emission computed tomography ((201)Tl-SPECT) in the detection of recurrences in the follow-up of patients with treated primary neuroepithelial tumours.
Sixty-three (201)Tl-SPECT were performed in 36 patients with glioma (12 males, mean age of 46 +/- 13 years). All patients underwent surgery and adjuvant radiotherapy (and some of them received chemotherapy). All patients were submitted to morphological neuroimaging techniques as well (and (201) Tl-SPECT). Mean follow-up was 18.3 +/- 14.6 months. Gold standard was based on clinical follow-up, therapeutical decisions (at least 4 months after (201)Tl-SPECT) and imaging features.
Sensitivity and specificity of (201)Tl-SPECT to detect glioma recurrences were 90% and 100% respectively and 93% accuracy. Sensitivity and specificity for high grade tumours, were 100% respectively. Due to 4 false negatives, sensitivity and specificity for low grade gliomas were 78% and 100%. In the positive (201)Tl-SPECT group of patients overall survival was 13.64% at the end of the study. The negative (201)Tl-SPECT group had 84.62% overall survival at the end of the study (p = 0.0003). CONCLUSIONS. (201)Tl-SPECT is a valuable and noninvasive diagnostic procedure to detect recurrence or progression disease for treated gliomas and ependymomas. (201)Tl-SPECT has a good correlation with short term prognosis with excellent diagnostic accuracy.
本研究的目的是确定铊 -（201）单光子发射计算机断层扫描（（201）Tl - SPECT）在接受原发性神经上皮肿瘤治疗患者随访中检测复发情况的价值。
对36例神经胶质瘤患者（12例男性，平均年龄46±13岁）进行了63次（201）Tl - SPECT检查。所有患者均接受了手术及辅助放疗（部分患者还接受了化疗）。所有患者也都接受了形态学神经成像技术检查（以及（201）Tl - SPECT检查）。平均随访时间为18.3±14.6个月。金标准基于临床随访、治疗决策（（201）Tl - SPECT检查后至少4个月）及影像学特征。
（201）Tl - SPECT检测神经胶质瘤复发的敏感性和特异性分别为90%和100%，准确率为93%。高级别肿瘤的敏感性和特异性分别为100%。由于4例假阴性结果，低级别神经胶质瘤的敏感性和特异性分别为78%和100%。在研究结束时，（201）Tl - SPECT检查结果为阳性的患者组总体生存率为13.64%。（201）Tl - SPECT检查结果为阴性的患者组在研究结束时总体生存率为84.62%（p = 0.0003）。结论。（201）Tl - SPECT是一种有价值的非侵入性诊断方法，可用于检测治疗后的神经胶质瘤和室管膜瘤的复发或疾病进展。（201）Tl - SPECT与短期预后具有良好的相关性，诊断准确性极佳。
